These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25995284)

  • 41. Pregnancy associated plasma protein A in Down's syndrome.
    Cuckle H; Lilford RJ; Teisner B; Holding S; Chard T; Grudzinskas JG
    BMJ; 1992 Aug; 305(6850):425. PubMed ID: 1382769
    [No Abstract]   [Full Text] [Related]  

  • 42. Pregnancy associated plasma protein A in Down's syndrome.
    Macintosh MC; Chard T
    BMJ; 1992 Aug; 305(6850):425. PubMed ID: 1382770
    [No Abstract]   [Full Text] [Related]  

  • 43. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy.
    Odibo A
    Br J Obstet Gynaecol; 1996 Nov; 103(11):1173-4. PubMed ID: 8917014
    [No Abstract]   [Full Text] [Related]  

  • 44. Quantitative performance of antibody array technology in a prenatal screening setting.
    Rodenburg W; Reimerink JH; Imholz S; Godeke GJ; Pennings JL; Schielen PC; Koster MP; de Vries A
    Clin Chem Lab Med; 2011 Oct; 50(2):325-32. PubMed ID: 22035138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy.
    Muller F; Cuckle H; Teisner B; Grudzinskas JG
    Prenat Diagn; 1993 Jul; 13(7):633-6. PubMed ID: 7692431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can safety assurance procedures in the food industry be used to evaluate a medical screening programme? The application of the Hazard Analysis and Critical Control Point system to an antenatal serum screening programme for Down's syndrome. Stage 2: overcoming the hazards in programme delivery.
    Derrington MC; Draper ES; Hsu RT; Kurinczuk JJ
    J Eval Clin Pract; 2003 Feb; 9(1):49-57. PubMed ID: 12558702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Presentation of screen negative results on serum screening for Down's syndrome: variations across Britain.
    Allanson A; Michie S; Marteau TM
    J Med Screen; 1997; 4(1):21-2. PubMed ID: 9200058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety first: choices in antenatal screening for Down's syndrome.
    Canick J
    J Med Screen; 2003; 10(2):55. PubMed ID: 12831122
    [No Abstract]   [Full Text] [Related]  

  • 49. Down's syndrome screening: where to now?
    Whittle M
    BJOG; 2001 Jun; 108(6):559-61. PubMed ID: 11426887
    [No Abstract]   [Full Text] [Related]  

  • 50. Screening for Down's syndrome.
    Keatinge R
    Lancet; 1992 Oct; 340(8826):1034. PubMed ID: 1357418
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation of marker values in Down's syndrome screening: the effect of dating error.
    Dunstan FD; Iles TC; Nix AB; Williams K
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():460-7. PubMed ID: 10456208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. False-negative results in Down's syndrome screening.
    Cavalli P
    Lancet; 1996 Apr; 347(9006):965-6. PubMed ID: 8598771
    [No Abstract]   [Full Text] [Related]  

  • 53. Antenatal screening for Down's syndrome.
    Reynolds TM
    Lancet; 1998 Oct; 352(9134):1145. PubMed ID: 9798611
    [No Abstract]   [Full Text] [Related]  

  • 54. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation.
    Wald NJ; Densem JW; George L; Muttukrishna S; Knight PG; Watt H; Hacksaw A; Morris JK
    Prenat Diagn; 1997 Mar; 17(3):285-90. PubMed ID: 9110376
    [No Abstract]   [Full Text] [Related]  

  • 55. Ethnic differences in outcome of serum screening for Down's syndrome. Differences in median values may account for differences in false positive rates.
    Ford C; Moore A; Bartlett WA; Jones AF
    BMJ; 1996 Apr; 312(7037):1040-1. PubMed ID: 8616371
    [No Abstract]   [Full Text] [Related]  

  • 56. Ethnic differences in outcome of serum screening for Down's syndrome. For appreciable ethnic differences in false positive rates, use different cut off points.
    Holloway PJ; Bulusu S
    BMJ; 1996 Apr; 312(7037):1041. PubMed ID: 8616372
    [No Abstract]   [Full Text] [Related]  

  • 57. Presentation of meta-analysis plots.
    Wald NJ; Bestwick JP
    J Med Screen; 2015 Mar; 22(1):49-51. PubMed ID: 25753762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reply of the authors.
    Bellver J; Serra V
    Fertil Steril; 2014 Mar; 101(3):e19. PubMed ID: 24462058
    [No Abstract]   [Full Text] [Related]  

  • 59. Comment on immunoassays developed for pregnancy-associated plasma protein-A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes.
    Fredericks S; Bertomeu-Gonzalez V; Petrovic I; Holt DW; Kaski JC
    Clin Chem; 2006 Aug; 52(8):1619-20. PubMed ID: 16873310
    [No Abstract]   [Full Text] [Related]  

  • 60. An ELISA for pregnancy-associated plasma protein A.
    Pledger DR; Belfield A
    Ann Clin Biochem; 1983 Jul; 20 (Pt 4)():236-40. PubMed ID: 6193752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.